All posts related to "patient input"

Reminder: Call for patient input on tofacitinib (Xeljanz®) for psoriatic arthritis

Megaphone GraphicDo you have psoriatic arthritis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Call for patient input on tofacitinib (Xeljanz®) for psoriatic arthritis

Megaphone GraphicDo you have psoriatic arthritis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Call for patient input on tapentadol hydrochloride (Nucynta) for the management of severe pain

stick man with megaphone for patient inputDo you have severe pain? We need your valuable input. 

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for tapentadol hydrochloride (Nucynta) for the management of pain severe enough to require daily, continuous, long-term opioid treatment, and:

  • that is opioid-responsive; and
  • for which alternative treatment options are inadequate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost-effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Call for patient input on ixekizumab (Taltz) for the treatment of psoriatic arthritis

Stickman with megaphone calling for patient inputDo you have psoriatic arthritis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for ixekizumab (Taltz) for the treatment of psoriatic arthritis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Let BC PharmaCare hear “Your Voice” on tocilizumab (Actemra™) 

Stick Man figure holding MegaphoneBC PharmaCare is looking for your input on tocilizumab (Actemra™) for the treatment of giant cell arteritis

Tocilizumab (Actemra®) for giant cell arteritis (GCA) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about tocilizumab for the treatment of GCA.

You can give input if you are a B.C. resident and have giant cell arteritis, a caregiver to someone with giant cell arteritis, or if your group represents people who live with giant cell arteritis.

If you would like our help in providing your input, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Monday, February 19 so that we may submit the questionnaire in time for the deadline.

The submission deadline is midnight on February 21, 2018. Patients and caregivers may give their input directly through the links below.

Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:

  • To view the information sheet for tocilizumab for giant cell arteritis: click here
  • For the Patient Questionnaire: click here
  • For the Caregiver Questionnaire: click here
  • For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)

Call for patient input on brodalumab for moderate to severe plaque psoriasis

Stickman with megaphone calling for patient inputDo you have moderate to severe plaque psoriasis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for brodalumab for moderate to severe plaque psoriasis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Call for patient input on tocilizumab (Actemra®) for giant cell arteritis

Stickman with megaphone calling for patient inputCall for patient input on tocilizumab (Actemra®) for giant cell arteritis

Do you have giant cell arteritis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for tocilizumab (Actemra®) for the treatment of giant cell arteritis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis?

Stickman with megaphone calling for patient inputCall for patient input on biosimilar infliximab (Merck) for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis? We need your valuable input

Health Canada defines biosimilars as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Remicade®).

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The originator biologic, or reference product, is infliximab (Remicade®).

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Call for patient input on guselkumab for moderate to severe plaque psoriasis

Stickman with megaphone calling for patient inputDo you have moderate to severe plaque psoriasis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for guselkumab for the treatment of moderate to severe plaque psoriasis.

Guselkumab belongs to the biologic response modifier class of inflammatory arthritis medications. It works by blocking the interleukin (IL)-23 molecule, a cytokine that plays a key role in plaque psoriasis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about public reimbursement of medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Let BC PharmaCare hear “Your Voice” on sarilumab

Stickman with megaphone calling for Your Voice patient inputBC PharmaCare is looking for your input on sarilumab for the treatment of rheumatoid arthritis

Sarilumab (Kevzara™) is a fully human monoclonal antibody that targets IL-6, a protein central to the development of the signs and symptoms of rheumatoid arthritis. Sarilumab can be used alone or in combination with methotrexate or other traditional disease-modifying antirheumatic drugs (DMARDs). It is given by subcutaneous (under the skin) injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program.  Continue reading